Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10491222 | 1.00 | GSK3A (0.31) | GSK3AGSK3BMGLL | |
| Hydrochloric Acid SCHEMBL28815853 | 0.75 | MGLL (0.36) | GSK3AGSK3BMGLL | |
| SCHEMBL27421027 | 0.72 | MGLL (0.38) | GSK3AGSK3BMGLL | |
| SCHEMBL9414032 | 0.71 | GSK3A (0.31) | GSK3AGSK3BMGLL | |
| SCHEMBL3813596 | 0.71 | MGLL (0.32) | GSK3AGSK3BMGLL | |
| SCHEMBL822300 | 0.71 | GSK3A (0.31) | GSK3AGSK3BMGLL | |
| SCHEMBL8989652 | 0.71 | GSK3A (0.31) | GSK3AGSK3BMGLL | |
| Hydrochloric Acid SCHEMBL354779 | 0.70 | MGLL (0.39) | GSK3AGSK3BMGLL | |
| SCHEMBL3259474 | 0.70 | CASP3 (0.44) | — | |
| SCHEMBL27580159 | 0.68 | MGLL (0.33) | GSK3AGSK3BMGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020192703-A1 | Immunoassay reagents and methods for determination of LSD and LSD metabolites | MICROGENICS CORPORATION | 2002-12-19 | — | — | US | claimed |
| EP-0820984-B1 | Activated amphetamines | ROCHE DIAGNOSTICS GMBH (DE) | 2002-03-27 | — | — | EP | claimed |
| EP-0429611-B1 | AMINOALKYL MALEIMIDES AND HAPTENE AND ANTIGEN DERIVATIVES THEREOF AND CONJUGATES WITH PEPTIDES OR PROTEINS | ROCHE DIAGNOSTICS GMBH (DE) | 2001-02-28 | — | — | EP | claimed |
| US-5595741-A | Aminoalkylmaleimides and hapten and antigen derivatives derived therefrom as well as conjugates with peptides or proteins | BOEHRINGER MANNHEIM GMBH (DE) | 1997-01-21 | — | — | US | claimed |
| EP-0429611-A1 | AMINOALKYL MALEIMIDES AND HAPTENE AND ANTIGEN DERIVATIVES THEREOF AND CONJUGATES WITH PEPTIDES OR PROTEINS | Roche Diagnostics GmbH (DE) | 1991-06-05 | — | — | EP | claimed |
| WO-1990015798-A1 | AMINOALKYL MALEIMIDES AND HAPTENE AND ANTIGEN DERIVATIVES THEREOF AND CONJUGATES WITH PEPTIDES OR PROTEINS | BOEHRINGER MANNHEIM GMBH (DE) | 1990-12-27 | — | — | WO | claimed |
| US-20240059732-A1 | Antibody-Drug Conjugates Including Hemiasterlin Derivative | Sumitomo Pharma Co., Ltd. (JP) | 2024-02-22 | — | — | US | disclosed |
| EP-3666787-B1 | ANTIBODY-DRUG CONJUGATES INCLUDING HEMIASTERLIN DERIVATIVE | SUMITOMO PHARMA CO LTD (JP) | 2024-02-21 | — | — | EP | disclosed |
| US-11795195-B2 | Antibody-drug conjugates including hemiasterlin derivative | Sumitomo Pharma Co., Ltd. (JP) | 2023-10-24 | — | — | US | disclosed |
| US-20230050863-A1 | DICATIONIC FLUORESCENT DYES | ROCHE MOLECULAR SYSTEMS, INC. | 2023-02-16 | — | — | US | disclosed |
| US-20220202948-A1 | Agent for Eliminating Pluripotent Stem Cells | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-06-30 | — | — | US | disclosed |
| US-20220144889-A1 | Hemiasterlin Derivative Having Cysteine Residue | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-05-12 | — | — | US | disclosed |
| EP-3925668-A1 | HEMIASTERLIN DERIVATIVE HAVING CYSTEINE RESIDUE | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2021-12-22 | — | — | EP | disclosed |
| EP-0742903-A1 | PIPERIDINE ANALOGS AND CONJUGATES OF PROCAINAMIDE AND NAPA | BOEHRINGER MANNHEIM CORPORATION (US) | 1996-11-20 | — | — | EP | disclosed |
| US-5525474-A | IMMUNOASSAY; LINKING THE HAPTENIC DRUG VIA ITS MALEIMIDE MOIETY AND A SULFHYDRYL BRIDGE TO AN IMMUNOGENIC CARRIER TO STIMULATE ANTIBODIES | BOEHRINGER MANNHEIM CORPORATION (US) | 1996-06-11 | — | — | US | disclosed |
| WO-1995020763-A1 | PIPERIDINE ANALOGS AND CONJUGATES OF PROCAINAMIDE AND NAPA | BOEHRINGER MANNHEIM CORPORATION (US) | 1995-08-03 | — | — | WO | disclosed |
| EP-0429611-A1 | AMINOALKYL MALEIMIDES AND HAPTENE AND ANTIGEN DERIVATIVES THEREOF AND CONJUGATES WITH PEPTIDES OR PROTEINS | Roche Diagnostics GmbH (DE) | 1991-06-05 | — | — | EP | disclosed |
| EP-0429611-A1 | AMINOALKYL MALEIMIDES AND HAPTENE AND ANTIGEN DERIVATIVES THEREOF AND CONJUGATES WITH PEPTIDES OR PROTEINS | Roche Diagnostics GmbH (DE) | 1991-06-05 | — | — | EP | disclosed |
| WO-1990015798-A1 | AMINOALKYL MALEIMIDES AND HAPTENE AND ANTIGEN DERIVATIVES THEREOF AND CONJUGATES WITH PEPTIDES OR PROTEINS | BOEHRINGER MANNHEIM GMBH (DE) | 1990-12-27 | — | — | WO | disclosed |
| WO-1990015798-A1 | AMINOALKYL MALEIMIDES AND HAPTENE AND ANTIGEN DERIVATIVES THEREOF AND CONJUGATES WITH PEPTIDES OR PROTEINS | BOEHRINGER MANNHEIM GMBH (DE) | 1990-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144889-A1 | Hemiasterlin Derivative Having Cysteine Residue | SHBG, CYP11A1, CYP11B1 | GSK3A 2144/4885GSK3B 2216/4885MGLL 2576/4885 |
| US-20220202948-A1 | Agent for Eliminating Pluripotent Stem Cells | POU5F1, POU2F1, POU2F2 | GSK3A 1841/4885GSK3B 1765/4885MGLL 4650/4885 |
| US-11795195-B2 | Antibody-drug conjugates including hemiasterlin derivative | HSD3B2, HSD3B1, HSD11B2 | GSK3A 333/4885GSK3B 229/4885MGLL 4801/4885 |
| US-20240059732-A1 | Antibody-Drug Conjugates Including Hemiasterlin Derivative | HSD3B2, HSD3B1, HSD11B2 | GSK3A 333/4885GSK3B 229/4885MGLL 4801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.